Ireland
--:--IST
Priya Life Science Sponsor trial record
Sponsor · clinical trials

Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our France register with Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida as lead sponsor. Synced 18 Nov 2026
6Current trials
6Recruiting now
2Drugs in these trials
1Trial register
At a glance

Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida is the lead sponsor of 6 current clinical trials in our France register. 6 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Doravirine and Lenacapavir. The most-studied condition is HIV Infections.

ClinicalTrials.gov trials by status

  • Recruiting6100%

Trials by phase

  • Observational350%
  • Phase 2233%
  • Not applicable117%
01

Clinical trials sponsored by Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida

6 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Real World Use of Lenacapavir, as an add-on to an Optimized Background Regimen in France
NCT06799338 · ClinicalTrials.gov ↗ · HIV I Infection
Observational Recruiting 2025-03 France
Evolution of the Clinical, Immuno-virological and Aging Trajectory of Patients Living With HIV
NCT06258122 · ClinicalTrials.gov ↗ · HIV Infections
Observational Recruiting 2024-04 France
Doravirine/Lamivudine (DOR/3TC) as a Maintenance ART in Comparison With Dolutegravir/Lamivudine (DTG/3TC) in PLWH Successfully
NCT06774872 · ClinicalTrials.gov ↗ · HIV-1-infection
Phase 2 Recruiting 2025-04 France
HIV-1 Infected Patients, Phase II Trial, Dual Combination Doravirine/Raltegravir Open Label
NCT04513626 · ClinicalTrials.gov ↗ · HIV Infections
Phase 2 Recruiting 2020-09 France
Cohort of Women Living With HIV-1 and Receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide
NCT07921472 · ClinicalTrials.gov ↗ · HIV (Human Immunodeficiency Virus), Pregnancy
Observational Recruiting 2026-05 France
Evaluation of the Acceptability and Impact of a Sexual Health Screening and Prevention Program for Vulnerable Women
NCT06996938 · ClinicalTrials.gov ↗ · Vulnerable Population
Not applicable Recruiting 2025-03 France

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida trials

2 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida trials

6 conditions
HIV Infections2HIV I Infection1HIV-1-infection1HIV (Human Immunodeficiency Virus)1Pregnancy1Vulnerable Population1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in France66

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in HIV Infections

SponsorTrials
ViiV Healthcare20
Oswaldo Cruz Foundation3
Kirby Institute2
Hôpital Européen Marseille2
Liaoning Chengda Biotechnology1
PENTA Foundation1
Memorial University of Newfoundland1
José Antonio Mata Marín1

Sponsors with the most current trials registered for this condition.

06

Questions about Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida trials

How many clinical trials does Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida sponsor?

Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida is the lead sponsor of 6 current trials on ClinicalTrials.gov in our France register, as of the registry sync on 18 November 2026. Completed and withdrawn studies are not counted.

Are Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida trials recruiting?

Yes. 6 of its 6 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida testing?

Its current trials name 2 drugs and biologicals as interventions. The most frequent are Doravirine (1) and Lenacapavir (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 18 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.